

Zogenix to Release First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 8

May 1, 2019

EMERYVILLE, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three months ended March 31, 2019, after the market close, and will host a corporate update conference call and webcast on Wednesday, May 8, 2019, at 4:30 PM Eastern Time.

Conference Call Details

Wednesday, May 8, at 4:30 PM Eastern Time/1:30 PM Pacific Time

Toll Free: 877-407-9716

International: 201-493-6779

Conference ID: 13689677

Webcast: <http://public.viavid.com/index.php?id=134029>

About Zogenix

Zogenix is a global pharmaceutical company committed to developing and commercializing transformative therapies to improve the lives of patients and their families living with rare diseases. The company's MAA for its lead candidate FINTEPLA® (ZX008, fenfluramine) has been accepted for review by the European Medicines Agency and is in development in Japan. Zogenix is preparing for a Type A meeting with the U.S. Food & Drug Administration to discuss resubmission of the company's NDA. For more information, visit www.zogenix.com.

CONTACTS:

Zogenix

Melinda Baker

Senior Director, Corporate Communications

media@zogenix.com

Media

Rachel Lipsitz

Public Relations, Syneos Health

+1 (858) 449 9575 | rachel.lipsitz@syneoshealth.com

Investors

Andrew McDonald

Founding Partner, LifeSci Advisors LLC

+1 (646) 597-6987 | Andrew@lifesciadvisors.com

The logo for Zogenix, featuring the word "ZOGENIX" in a bold, purple, sans-serif font. A green swoosh underline is positioned beneath the letters "O" and "G".

Source: Zogenix, Inc.